The recombinant proteins market is witnessing growth and is projected to reach USD 3,203.7 million by 2030. The increasing occurrence of numerous rare illnesses, like neutropenia, multiple sclerosis, anemia, cerebral apoplexy, and dwarfism, is driving the need for medications on the basis of recombinant proteins.

Furthermore, such agents are utilized in the advancements of novel treatments for severe chronic illnesses, such as cardiovascular diseases, cancer, viral diseases, and endocrine diseases. The surge in the incidence of these conditions is projected to drive the requirement for recombinant protein medications in the near future.

In recent years, the chemokines category led the market, and the category is also projected to dominate the market in the future as well. This growth of the category can be credited to the utilization of development reasons and chemokines in numerous research studies on cancer, neurobiology, immunology, COVID-19, and HIV/AIDS.

The APAC industry is projected to grow at the fastest pace in the coming few years. This can be ascribed to the widespread development in pharmaceutical contract development and production efforts in the past few years.

Furthermore, the increasing populace and its rising need for better accessibility to drugs; and the reduced cost of biopharmaceuticals, with the introduction of lucrative generics are leading to the development of the market in the region.

Additionally, rising GDP per capita, government-supportive healthcare steps, and rapid urbanization rate have extended the potential for the acceptance of recombinant proteins in the region.